Free Trial
NASDAQ:AKBA

Akebia Therapeutics (AKBA) Stock Price, News & Analysis

Akebia Therapeutics logo
$2.07 +0.14 (+7.25%)
As of 01/17/2025 04:00 PM Eastern

About Akebia Therapeutics Stock (NASDAQ:AKBA)

Key Stats

Today's Range
$1.92
$2.09
50-Day Range
$1.75
$2.13
52-Week Range
$0.80
$2.48
Volume
6.51 million shs
Average Volume
2.50 million shs
Market Capitalization
$451.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.50
Consensus Rating
Buy

Company Overview

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Akebia Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
78th Percentile Overall Score

AKBA MarketRank™: 

Akebia Therapeutics scored higher than 78% of companies evaluated by MarketBeat, and ranked 292nd out of 948 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Akebia Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Akebia Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Akebia Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Akebia Therapeutics are expected to grow in the coming year, from ($0.26) to $0.08 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Akebia Therapeutics is -9.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Akebia Therapeutics is -9.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Akebia Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    7.65% of the outstanding shares of Akebia Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Akebia Therapeutics has a short interest ratio ("days to cover") of 7.9.
  • Change versus previous month

    Short interest in Akebia Therapeutics has recently increased by 18.55%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Akebia Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Akebia Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.65% of the outstanding shares of Akebia Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Akebia Therapeutics has a short interest ratio ("days to cover") of 7.9.
  • Change versus previous month

    Short interest in Akebia Therapeutics has recently increased by 18.55%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Akebia Therapeutics has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 19 news articles for Akebia Therapeutics this week, compared to 3 articles on an average week.
  • Search Interest

    24 people have searched for AKBA on MarketBeat in the last 30 days. This is an increase of 1,100% compared to the previous 30 days.
  • MarketBeat Follows

    11 people have added Akebia Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 267% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Akebia Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.10% of the stock of Akebia Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 33.92% of the stock of Akebia Therapeutics is held by institutions.

  • Read more about Akebia Therapeutics' insider trading history.
Receive AKBA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akebia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AKBA Stock News Headlines

What is HC Wainwright's Estimate for AKBA FY2029 Earnings?
Grab This Altcoin Before Trump's Crypto Announcement
Grab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which is why I'm recommending ONE coin to all investors right now.
Akebia announces ‘multiple positive business updates’
See More Headlines

AKBA Stock Analysis - Frequently Asked Questions

Akebia Therapeutics' stock was trading at $1.90 at the beginning of the year. Since then, AKBA shares have increased by 8.9% and is now trading at $2.07.
View the best growth stocks for 2025 here
.

Akebia Therapeutics, Inc. (NASDAQ:AKBA) issued its quarterly earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.04) by $0.06. The biopharmaceutical company earned $37.43 million during the quarter, compared to analyst estimates of $45.66 million.

Top institutional shareholders of Akebia Therapeutics include SG Americas Securities LLC (0.05%) and Empirical Asset Management LLC (0.01%). Insiders that own company stock include John P Butler, Steven Keith Burke, Michel Dahan, Nicole R Hadas, David A Spellman and Violetta Cotreau.
View institutional ownership trends
.

Shares of AKBA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Akebia Therapeutics investors own include Novavax (NVAX), NVIDIA (NVDA), Tesla (TSLA), Meta Platforms (META), Advanced Micro Devices (AMD), Intel (INTC) and Exxon Mobil (XOM).

Company Calendar

Last Earnings
11/07/2024
Today
1/18/2025
Next Earnings (Estimated)
3/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AKBA
Employees
430
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.50
High Stock Price Target
$7.50
Low Stock Price Target
$7.50
Potential Upside/Downside
+262.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-51,920,000.00
Pretax Margin
-27.08%

Debt

Sales & Book Value

Annual Sales
$194.62 million
Book Value
($0.16) per share

Miscellaneous

Free Float
209,236,000
Market Cap
$451.63 million
Optionable
Optionable
Beta
0.72

Social Links

(Almost)  Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

This page (NASDAQ:AKBA) was last updated on 1/18/2025 by MarketBeat.com Staff
From Our Partners